Armando Anido
Independent DirectorMr. Armando Anido, MBA, has been the Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, Inc. since October 2014. Mr. Anido has been an Independent Director of SCYNEXIS, Inc. since January 21, 2019. He has executive, operational and commercial leadership experience in the biopharmaceutical industry and he launched over 10 prescription medications in several therapeutic areas. He has broad understanding of key issues in the biotechnology industry, including sales and marketing, development and commercialization, strategy and operations and has extensive executive experience in senior leadership and Director roles at several biotechnology companies. Prior to joining Zynerba, he served as a Business Consultant to the life science industry from May 2014 to October 2014. He served as the Chief Executive Officer at NuPathe, Inc., from July 25, 2012 to March 2014. He served as the Chief Executive and President of Auxilium Pharmaceuticals Inc. from July 17, 2006 to December 7, 2011. Additionally, Mr. Anido led the company through the FDA approval and commercialization of Xiaflex®, an injectable collagenase for Dupuytren Contracture. Mr. Anido joined Auxilium in 2006 and grew sales. He served as the Executive Vice President of Sales and Marketing of MedImmune, LLC (alternate name MedImmune Inc.) from February 22, 2005 to January 5, 2006 and its Senior Vice President of Commercial Operations from February 2004 to February 2005 and Senior Vice President of Sales and Marketing since 1999. He served as the Chairman of the Commercial Strategy Team at MedImmune, Inc. and was responsible for the commercial management of its marketed brands. He held several senior marketing positions at GlaxoWellcome, Inc. and its predecessor companies. Prior to MedImmune, Inc. from 1995 to 1999, he served at GlaxoWellcome Inc., where he served as Vice President of Central Nervous System Marketing and also served as its Director of HIV Marketing. Prior to this time, Mr. Anido served in various positions at Lederle Laboratories from 1989 to 1995, including as its Vice President of Anti-Infectives Marketing. He has been a Director at Zynerba Pharmaceuticals, Inc. since 2014. He had been a Non-Executive Director of Altamira Therapeutics Ltd. (formerly known as Auris Medical Holding Ltd.) (formerly known as Auris Medical Holding AG) since April 14, 2016 uuntil 2023. He joined the Altamira Therapeutics Ltd. on April 14, 2016. He served as Independent Director of Aviragen Therapeutics, Inc. since October 2015 until March 2018. He is a Member of the Board of Directors of Biota Pharmaceuticals, Inc. He served as a Director of Respira Therapeutics, Inc., from May 2012 to September 2014 and Adolor Corporation from September 2003 to December 2011. He served as a Director of NuPathe, Inc., from July 25, 2012 to March 2014 and Vaxart, Inc. He served as a Director of Auxilium Pharmaceuticals from July 17, 2006 to December 7, 2011. He is a Registered Pharmacist. Mr. Anido holds an MBA in Marketing and Finance and a BS in Pharmacy from West Virginia University.
Positions
- Company NameSCYNEXIS, Inc.Stock CodeSCYXPositionIndependent DirectorColleagues
- DGDavid Gonzalez AnguloCEO, President & Director
- GMGuy MacDonaldIndependent Chairman of the Board
- SSScott SukenickChief Legal Officer & Corporate Secretary
- SSSanjay S. SubramanianChief Financial Officer
- DGDaniella GiganteVice President of Human Resources & Information Technology
- TMTodd MingaSenior Vice President of Research & Development
- AFAnn F. HanhamIndependent Director
- DCDavid C. HastingsIndependent Director
